The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 30, 2024
Filed:
Aug. 01, 2017
Applicant:
Astellas Institute for Regenerative Medicine, Westborough, MA (US);
Inventors:
Kathryn L. McCabe, Westborough, MA (US);
Shi-Jiang Lu, Shrewsbury, MA (US);
Robert P. Lanza, Clinton, MA (US);
Assignee:
Astellas Institute for Regenerative Medicine, Westborough, MA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 5/071 (2010.01); A61K 9/00 (2006.01); A61K 35/30 (2015.01); A61K 45/06 (2006.01); A61L 27/38 (2006.01); C12N 5/07 (2010.01); C12N 5/074 (2010.01); C12N 5/079 (2010.01); C12N 5/0797 (2010.01); C12N 5/16 (2006.01);
U.S. Cl.
CPC ...
C12N 5/0621 (2013.01); A61K 9/0048 (2013.01); A61K 35/30 (2013.01); A61K 45/06 (2013.01); A61L 27/3808 (2013.01); A61L 27/3839 (2013.01); A61L 27/3895 (2013.01); C12N 5/0623 (2013.01); A61L 2430/16 (2013.01); C12N 2500/60 (2013.01); C12N 2500/90 (2013.01); C12N 2501/115 (2013.01); C12N 2501/135 (2013.01); C12N 2501/15 (2013.01); C12N 2501/155 (2013.01); C12N 2501/40 (2013.01); C12N 2501/415 (2013.01); C12N 2501/727 (2013.01); C12N 2501/999 (2013.01); C12N 2506/02 (2013.01); C12N 2506/08 (2013.01); C12N 2506/45 (2013.01); C12N 2533/50 (2013.01);
Abstract
This disclosure generally relates to cell-based therapies for treatment of visual disorders, including disorders of the cornea. Methods are exemplified for directed differentiation of corneal cells from stem cells. Compositions of corneal endothelial cells and uses thereof are also provided. Exemplary compositions exhibit improved cell density and/or more 'youthful' gene expression relative to cells obtained from donated tissue.